Ibio Inc represents a strong set of values and corporate philosophy. The company focuses on advancing plant-based biopharmaceutical technologies to provide innovative solutions for various diseases. By combining their expertise in molecular biology and genetic engineering, Ibio aims to develop therapies and vaccines that are cost-effective, efficient, and accessible. Their commitment to sustainability and social responsibility is evident in their efforts to address global health challenges. Ibio Inc values collaboration, integrity, and continuous improvement to deliver high-quality biologics. With their dedication to research and development, Ibio Inc strives to make a positive impact in the field of biotechnology.

Ibio Inc is primarily present in the United States of America.

Ibio Inc has achieved several significant milestones over the years. One key achievement is the successful development of their plant-based protein expression technology platform known as FastPharming System. This platform allows for rapid production of biopharmaceuticals. Additionally, the company has made strides in partnership collaborations, including an agreement with AzarGen Biotechnologies to develop and manufacture biosimilar products. Ibio Inc has also made progress in advancing their own pipeline, with the initiation of clinical trials for their lead candidate IBIO-100. These milestones highlight the company's dedication to advancing biopharmaceutical innovation and establishing strong partnerships for future growth.

Ibio Inc is a biotechnology company that specializes in the development and manufacture of therapeutic proteins. Established in 2008, the company is headquartered in Bryan, Texas. Ibio Inc focuses on developing proprietary products and technologies for the treatment of various diseases, including cancer, infectious diseases, and autoimmune disorders. With its advanced plant-based protein expression platform, Ibio Inc enables efficient, cost-effective, and scalable production of biologics. The company has formed successful partnerships with major pharmaceutical companies, leveraging its expertise in protein expression and process development. Notably, Ibio Inc has a strong commitment to addressing unmet medical needs through innovative and sustainable solutions.

The main competitors of Ibio Inc in the market are companies such as Emergent BioSolutions, Inc., Novavax Inc., and Regeneron Pharmaceuticals Inc.

Ibio Inc is primarily active in the biotechnology industry.

The business model of Ibio Inc is focused on the development and commercialization of plant-based biopharmaceutical products. The company utilizes its proprietary technology, the iBioLaunch platform, to produce high-quality, cost-effective biotherapeutics and vaccines. With a focus on speed, scalability, and flexibility, Ibio Inc partners with pharmaceutical and biotechnology companies to advance their product development and manufacturing objectives. By leveraging the advantages of plant-based systems, Ibio Inc aims to provide efficient production solutions for a wide range of medical conditions, including cancer, infectious diseases, and autoimmune disorders.

مُعامل القيمة السوقية إلى الأرباح لـ Ibio هو ؜-٠٫٤١.

مُعامِل القيمة إلى المبيعات Ibio هو ٤٥٫٢٩.

نقاط جودة AlleAktien لـ Ibio هي 3/10.

Ibio الإيرادات هي ٢٢٥٬٠٠٠٫٠٠ USD.

صافي الربح Ibio هو ؜-٢٤٫٩١ مليون. USD.

Ibio Inc is a company specialized in the development and production of innovative vaccines and therapeutics. Its business model is based on three different divisions: the development of vaccines and therapeutics, the production of pharmaceutical ingredients, and the development and production of plant proteins.

يوزع Ibio أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Ibio في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـIbio هو US4510332038.

رمز WKN لـ Ibio هو A2JNBU.

الرمز المُختصر لـ Ibio هو IBIO.

خلال آخر 12 شهراً، دفعت Ibio توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Ibio خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Ibio هي .

Ibio يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Ibio دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Ibio يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Ibio المُعلن عنها في ٧‏/١١‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٧‏/١١‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٧‏/١١‏/٢٠٢٤.

في العام 2023، وزعت Ibio 0 USD كأرباح أسهم.

يتم توزيع أرباح Ibio بالعملة USD.